Up next soon: A new cancer indication to enter Ph. 1bThat should logically be GBM, as per the most recent presentation but nevetheless, another indication will be brought into clinical trial once NMIBC Ph. 2b is well underway.
"... The Company expects to investigate the commencement of an additional Phase Ib clinical study for a new cancer indication after Study II is well underway."